For the Inventor, By the Inventor

Enter assignee name

Bedminster, NJ, United States of America

Nps Pharmaceuticals, Inc.

USPTO Granted Patents = 93

CIPO Patents = 8

EPO Patents = 8

Trademarks = 8

Forward Citations = 1,302

Loading Chart...

Loading Chart...

103 inventors (with patents filed for the assignee):

Scott T Moe (20 out of 21 patents)

Bradford C Van Wagenen (19 out of 25 patents)

Manuel F Balandrin (18 out of 22 patents)

4. Karen J Krapcho (14 out of 14 patents)

5. Eric G DelMar (14 out of 17 patents)

6. Robert M Kral, Jr (12 out of 12 patents)

7. Thomas M Stormann (11 out of 14 patents)

8. Bradford C VanWagenen (11 out of 11 patents)

9. Robert M Barmore (10 out of 12 patents)

10. Alan L Mueller (9 out of 10 patents)

11. Janice H Johnson (9 out of 9 patents)

12. Lance G Hammerland (8 out of 8 patents)

13. Thomas B Marriott (7 out of 25 patents)

14. Linda D Artman (7 out of 8 patents)

15. Daryl Lynn Smith (6 out of 13 patents)

Core Competencies:

GLP-2 Receptor Modulators

Short Bowel Syndrome

Bone Resorption Diseases

Glucagon-Like Peptide-2

Calcium Receptor Active Compounds

Metabotropic Glutamate Receptor Antagonists

Sustained-Release Formulations

Neurological Disorders

Anxiety Disorders

Therapeutic Injections

Heteropolycyclic Compounds

Ex Vivo Methods

93 patents: Sort by Forward Citations

1. 9782455 - Solid phase synthesis of h(Gly2)GLP-2 (2017-10-10),

2. 9555079 - Treatment of short bowel syndrome patients with colon-in-continuity (2017-01-31),

3. 9545435 - Treatment of short bowel syndrome patients with colon-in-continuity (2017-01-17),

4. 9545434 - Treatment of short bowel syndrome patients with colon-in-continuity (2017-01-17),

5. 9539310 - Treatment of short bowel syndrome patients with colon-in-continuity (2017-01-10),

6. 9060992 - Treatment of short bowel syndrome patients with colon-in-continuity (2015-06-23),

7. 8980567 - Ex vivo method for determining potential GLP-2 receptor modulators (2015-03-17),

8. 8933039 - Glucagon-like peptide-2 analogs (2015-01-13),

9. 8765674 - Methods useful in the treatment of bone resorption diseases (2014-07-01),

10. 8592553 - Cloned glucagon-like peptide-2 receptors (2013-11-26),

11. 8481276 - Ex vivo method for determining potential GLP-2 receptor modulators (2013-07-09),

12. 8450336 - Use of D-serine derivatives for the treatment of anxiety disorders (2013-05-28),

13. 8257983 - Ex vivo method for determining potential GLP-2 receptor modulators (2012-09-04),

14. 8153588 - Methods useful in the treatment of bone resorption diseases (2012-04-10),

15. 8148508 - Method for enzymatic production of GLP-2(1-33) and GLP-2(1-34) peptides (2012-04-03),

NPS Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes innovative medicines for patients with rare diseases. They focus on diseases with high unmet medical needs and strive to improve the lives of those affected. NPS Pharmaceuticals aims to provide effective and safe treatment options through their research and development efforts. With a commitment to making a difference, they work towards addressing the challenges faced by patients and their families.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

93 Patents

#1 in Bedminster, NJ

#180 in New Jersey

#3,887 in US

#8,039 in the World

Bedminster, NJ, United States of America

Nps Pharmaceuticals, Inc.

Forward Citations = 1,302

103 inventors:

Scott T Moe (20 out of 21 patents)

Bradford C Van Wagenen (19 out of 25 patents)

Manuel F Balandrin (18 out of 22 patents)

4. Karen J Krapcho (14 out of 14 patents)

5. Eric G DelMar (14 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…